Base de dados : LILACS
Pesquisa : D02.455.326.397 [Categoria DeCS]
Referências encontradas : 3 [refinar]
Mostrando: 1 .. 3   no formato [Detalhado]

página 1 de 1

  1 / 3 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1087871
Autor: Arellano, Javier; Gonzalez, Ruben; Corredoira, Y; Núñez, Roxana.
Título: Diagnosis of elephantiasis nostras verrucosa as a clinical mani-festation of Kaposi's sarcoma / Diagnóstico de elefantiasis nostras verrucosa como mani-festación clínica del Sarcoma de Kaposi
Fonte: Medwave;20(1):e7767, 2020.
Idioma: en.
Resumo: Elephantiasis nostras verrucosa, a rare manifestation of Kaposi's sarcoma, is a progressive cutaneous hypertrophy caused by chronic non-filarial lymphedema secondary to obstruction of the lymphatic system that can lead to severe disfigurement of parts of the body that have gravity-dependent blood flow, due to edema, fibrosis, and hyperkeratosis, especially lower extremities. Among the various conditions that can induce chronic lymphedema are tumors, trauma, radiotherapy, obesity, hypothyroidism, chronic venous stasis, and AIDS-related Kaposi's sarcoma. Kaposi's sarcoma is a vascular tumor associated with the presence of human gammaherpesvirus 8 that is predominantly cutaneous, locally aggressive, with metastasis, and is associated with the production of factors that favor inflammation, lymphatic obstruction, and lymphedema.
Descritores: Sarcoma de Kaposi/complicações
Infecções Oportunistas Relacionadas com a AIDS/complicações
Elefantíase/diagnóstico
-Sarcoma de Kaposi/patologia
Sarcoma de Kaposi/tratamento farmacológico
Didanosina/uso terapêutico
Infecções Oportunistas Relacionadas com a AIDS/patologia
Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico
Lamivudina/uso terapêutico
Fármacos Anti-HIV/uso terapêutico
Ciclopropanos
Benzoxazinas/uso terapêutico
Quimioterapia Combinada
Elefantíase/etiologia
Elefantíase/patologia
Alcinos
Limites: Humanos
Masculino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: CL1.1 - Biblioteca Central


  2 / 3 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1003654
Autor: Amariles, Pedro; Galindo, Jaime; Mueses-Marín, Héctor F; Castañeda, Carol.
Título: Efectividad y seguridad del esquema genérico lamivudina/tenofovir y efavirenz en pacientes con VIH/SIDA naïve: estudio fase IV no aleatorizado, Cali-Colombia 2012-2014 / Effectiveness and safety of generic version of lamivudine/tenofovir and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2012-2014
Fonte: Rev. chil. infectol;36(1):32-40, feb. 2019. tab, graf.
Idioma: es.
Resumo: Resumen Antecedentes: Los estudios clínicos orientados a evaluar la calidad de medicamentos genéricos pueden ser útiles para fortalecer políticas de acceso a terapia anti-retroviral combinada (TARc). Objetivo: Describir la efectividad y seguridad del esquema genérico lamivudina/tenofovir/efavirenz (3TC/TDF/EFV) en pacientes con infección por VIH/SIDA naïve, pertenecientes a un programa de atención integral. Materiales/Métodos: Estudio clínico prospectivo fase IV abierto y sin grupo control. Entre 2012-2014, se incluyeron y siguieron 40 pacientes con infección por VIH/SIDA naïve y con indicación para iniciar tratamiento. Los pacientes fueron tratados con el esquema genérico 3TC/TDF/EFV y fueron seguidos durante 12 meses. El seguimiento incluyó valoración clínica, parámetros inmunovirológicos y de laboratorio, al inicio del tratamiento y a los 3, 6 y 12 meses. Resultados: De los 40 pacientes, 30 (75%) cumplieron los doce meses de tratamiento; de ellos, 80% alcanzó CV indetectable (< 40 copias/mL) y 83,3% CV < 50 copias/mL. Adicionalmente, en el grupo hubo un incremento en la mediana de 173 linfocitos TCD4/mm3. Por su parte, los resultados del hemograma completo, creatininemia y transaminasas hepáticas se conservaron en rangos normales y no generaron cambios del TARc. Los efectos adversos reconocidos para estos medicamentos se presentaron en menos de 10% de los pacientes y no tuvieron implicaciones graves. Conclusiones: En este grupo pequeño de pacientes, el esquema genérico 3TC/TDF/EFV es efectivo y seguro en el tratamiento de pacientes con infección por VIH/SIDA naïve, y su perfil de efectividad y seguridad es similar al del esquema 3TC/TDF/EFV innovador en pacientes con condiciones clínicas similares.

Background: Clinical studies aimed to evaluating the quality of generic drugs may be useful to strengthen policies of access to combined antiretroviral therapy (cART). Aim: To describe the effectiveness and safety of the generic schema lamivudine/tenofovir/efavirenz (3TC/TDF/EFV) in patients with HIV/AIDS naive, belonging to a comprehensive care program. Methods: A nonrandomized, open-label, phase IV study, during 2012 to 2014 naive HIV-infected patients 18 years or older with indication to receive cART were recruited. Patients were treated with generic scheme 3TC/TDF/EFV and were followed-up during 12 months. Clinical, immunological and laboratory parameters were assessed at baseline, 3, 6 and 12 months of treatment. Results: Of the 40 patients, 30 (75%) met the 12 months of treatment; of them, 80% achieved undetectable viral load (< 40 copies/mL) and 83.3% viral load < 50 copies/mL. Additionally, there was a significant increase (173 cells/mm3) in the median for CD4 T lymphocyte count. Moreover, the results of the whole blood count, creatinine and transaminases were preserved in normal ranges and did not generate changes in the cART. Potential side effects of antiretroviral drugs occurred in less than 10% of patients and had no serious implications. Conclusions: In this small group of patients, the generic scheme 3TC/TDF/EFV is effective and safe in the treatment of patients with HIV/AIDS naïve, and its effectiveness and safety profile is similar to show by innovator scheme 3TC/TDF/EFV in patients with similar clinical conditions. Registro Estudio: Registro Público Cubano de Ensayos Clínicos (RPCEC) ID: RPCEC00000134. Registered 20 July 2012.
Descritores: Síndrome de Imunodeficiência Adquirida/tratamento farmacológico
Medicamentos Genéricos/uso terapêutico
Lamivudina/uso terapêutico
Fármacos Anti-HIV/uso terapêutico
Benzoxazinas/uso terapêutico
Tenofovir/uso terapêutico
-Fatores de Tempo
Estudos Prospectivos
Reprodutibilidade dos Testes
Análise de Variância
Resultado do Tratamento
Colômbia
Estatísticas não Paramétricas
Ciclopropanos
Alcinos
Limites: Humanos
Masculino
Feminino
Adulto
Adulto Jovem
Tipo de Publ: Ensaio Clínico Fase IV
Responsável: CL1.1 - Biblioteca Central


  3 / 3 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Cunha, F. Q
Costa, R. S
Coimbra, T. M
Texto completo
Id: lil-618052
Autor: Francescato, H. D. C; Chierice, J. R. A; Marin, E. C. S; Cunha, F. Q; Costa, R. S; Silva, C. G. A; Coimbra, T. M.
Título: Effect of endogenous hydrogen sulfide inhibition on structural and functional renal disturbances induced by gentamicin
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;45(3):244-249, Mar. 2012. ilus, tab.
Idioma: en.
Resumo: Animal models of gentamicin nephrotoxicity present acute tubular necrosis associated with inflammation, which can contribute to intensify the renal damage. Hydrogen sulfide (H2S) is a signaling molecule involved in inflammation. We evaluated the effect of DL-propargylglycine (PAG), an inhibitor of endogenous H2S formation, on the renal damage induced by gentamicin. Male Wistar rats (N = 8) were injected with 40 mg/kg gentamicin (im) twice a day for 9 days, some of them also received PAG (N = 8, 10 mg·kg-1·day-1, ip). Control rats (N = 6) were treated with saline or PAG only (N = 4). Twenty-four-hour urine samples were collected one day after the end of these treatments, blood samples were collected, the animals were sacrificed, and the kidneys were removed for quantification of H2S formation and histological and immunohistochemical studies. Gentamicin-treated rats presented higher sodium and potassium fractional excretion, increased plasma creatinine [4.06 (3.00; 5.87) mg percent] and urea levels, a greater number of macrophages/monocytes, and a higher score for tubular interstitial lesions [3.50 (3.00; 4.00)] in the renal cortex. These changes were associated with increased H2S formation in the kidneys from gentamicin-treated rats (230.60 ± 38.62 µg·mg protein-1·h-1) compared to control (21.12 ± 1.63) and PAG (11.44 ± 3.08). Treatment with PAG reduced this increase (171.60 ± 18.34), the disturbances in plasma creatinine levels [2.20 (1.92; 4.60) mg percent], macrophage infiltration, and score for tubular interstitial lesions [2.00 (2.00; 3.00)]. However, PAG did not interfere with the increase in fractional sodium excretion provoked by gentamicin. The protective effect of PAG on gentamicin nephrotoxicity was related, at least in part, to decreased H2S formation.
Descritores: Alcinos/farmacologia
Antibacterianos/toxicidade
Gentamicinas/toxicidade
Glicina/análogos & derivados
Sulfeto de Hidrogênio/antagonistas & inibidores
Necrose Tubular Aguda/induzido quimicamente
-Creatinina/sangue
Glicina/farmacologia
Sulfeto de Hidrogênio/metabolismo
Imuno-Histoquímica
Necrose Tubular Aguda/tratamento farmacológico
Rim/metabolismo
Ratos Wistar
Fatores de Tempo
Limites: Animais
Masculino
Ratos
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde